Phathom Pharmaceuticals, Inc. Change in payables and accrued liability

Change in payables and accrued liability of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Change in payables and accrued liability growth rates and interactive chart.


Highlights and Quick Summary

  • Change in payables and accrued liability for the quarter ending June 29, 2021 was $-3.34 Million (a -64.86% decrease compared to previous quarter)
  • Year-over-year quarterly Change in payables and accrued liability decreased by -132.23%
  • Annual Change in payables and accrued liability for 2020 was $24 Million (a 960.0% increase from previous year)
  • Annual Change in payables and accrued liability for 2019 was $2.27 Million (a 906.67% increase from previous year)
  • Twelve month Change in payables and accrued liability ending June 29, 2021 was $3.02 Million (a -76.77% decrease compared to previous quarter)
  • Twelve month trailing Change in payables and accrued liability decreased by -82.3% year-over-year
Trailing Change in payables and accrued liability for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$3.02 Million $13 Million $24.1 Million $17.1 Million
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Change in payables and accrued liability of Phathom Pharmaceuticals, Inc.

Most recent Change in payables and accrued liabilityof PHAT including historical data for past 10 years.

Interactive Chart of Change in payables and accrued liability of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Change in payables and accrued liability for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-3.34 $-9.52
2020 $5.5 $10.38 $6.64 $1.57 $24.01
2019 $-1.53 $2.09 $1.31 $0.55 $2.27
2018 $0.1 $0.23

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.